UroGen Pharma Ltd. Cost of Revenue
UroGen Pharma Ltd. (URGN) reported Cost of Revenue of $6.57 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-05
- UroGen Pharma Ltd. cost of revenue for the quarter ending 2026-06-30 was $6.57M, a 85.13% increase year-over-year.
- UroGen Pharma Ltd. cost of revenue for the quarter ending 2026-03-31 was $4.14M, a 77.64% increase year-over-year.
- UroGen Pharma Ltd. cost of revenue for the quarter ending 2025-12-31 was $3.29M, a 33.10% increase year-over-year.
- UroGen Pharma Ltd. cost of revenue for the quarter ending 2025-09-30 was $3.28M, a 33.63% increase year-over-year.
- UroGen Pharma Ltd. cost of revenue for fiscal 2025 was $12.45M, a 40.15% increase from fiscal 2024.
- UroGen Pharma Ltd. cost of revenue for fiscal 2024 was $8.88M, a 5.13% decline from fiscal 2023.
- UroGen Pharma Ltd. cost of revenue for fiscal 2023 was $9.36M, a 22.30% increase from fiscal 2022.
- UroGen Pharma Ltd. cost of revenue for fiscal 2022 was $7.65M, a 48.42% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.57M 10-Q · filed 2026-08-05 | $10.71M 10-Q · filed 2026-08-05 | $14.00M derived: sum of 3 quarters · filed 2026-08-05 | $17.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $4.14M 10-Q · filed 2026-05-06 | $7.43M derived: sum of 2 quarters · filed 2026-05-06 | $10.71M derived: sum of 3 quarters · filed 2026-05-06 | $14.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $6.57M derived: sum of 2 quarters · filed 2026-03-02 | $10.12M derived: sum of 3 quarters · filed 2026-08-05 | $12.45M 10-K · filed 2026-03-02 |
| 2025-09-30 | $3.28M 10-Q · filed 2025-11-06 | $6.83M derived: sum of 2 quarters · filed 2026-08-05 | $9.16M 10-Q · filed 2025-11-06 | $11.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.55M 10-Q · filed 2026-08-05 | $5.88M 10-Q · filed 2026-08-05 | $8.35M derived: sum of 3 quarters · filed 2026-08-05 | $10.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.33M 10-Q · filed 2026-05-06 | $4.80M derived: sum of 2 quarters · filed 2026-05-06 | $7.25M derived: sum of 3 quarters · filed 2026-05-06 | $9.48M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.92M derived: sum of 2 quarters · filed 2026-03-02 | $7.15M derived: sum of 3 quarters · filed 2026-03-02 | $8.88M 10-K · filed 2026-03-02 |
| 2024-09-30 | $2.45M 10-Q · filed 2025-11-06 | $4.68M derived: sum of 2 quarters · filed 2025-11-06 | $6.41M 10-Q · filed 2025-11-06 | $8.70M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.23M 10-Q · filed 2025-08-07 | $3.96M 10-Q · filed 2025-08-07 | $6.24M derived: sum of 3 quarters · filed 2025-08-07 | $8.61M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.73M 10-Q · filed 2025-05-12 | $4.01M derived: sum of 2 quarters · filed 2025-05-12 | $6.38M derived: sum of 3 quarters · filed 2025-05-12 | $8.82M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $4.65M derived: sum of 2 quarters · filed 2025-03-10 | $7.10M derived: sum of 3 quarters · filed 2025-03-10 | $9.36M 10-K · filed 2025-03-10 |
| 2023-09-30 | $2.37M 10-Q · filed 2024-11-06 | $4.81M derived: sum of 2 quarters · filed 2024-11-06 | $7.08M 10-Q · filed 2024-11-06 | $9.34M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $2.44M 10-Q · filed 2024-08-13 | $4.71M 10-Q · filed 2024-08-13 | $6.97M derived: sum of 3 quarters · filed 2024-08-13 | $8.99M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $2.27M 10-Q · filed 2024-05-13 | $4.53M derived: sum of 2 quarters · filed 2024-05-13 | $6.55M derived: sum of 3 quarters · filed 2024-05-13 | $8.39M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $4.28M derived: sum of 2 quarters · filed 2024-03-14 | $6.13M derived: sum of 3 quarters · filed 2024-03-14 | $7.65M 10-K · filed 2024-03-14 |
| 2022-09-30 | $2.02M 10-Q · filed 2023-11-14 | $3.87M derived: sum of 2 quarters · filed 2023-11-14 | $5.39M 10-Q · filed 2023-11-14 | $6.98M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.85M 10-Q · filed 2023-08-10 | $3.37M 10-Q · filed 2023-08-10 | $4.96M derived: sum of 3 quarters · filed 2023-08-10 | $6.20M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.52M 10-Q · filed 2023-05-11 | $3.11M derived: sum of 2 quarters · filed 2023-05-11 | $4.36M derived: sum of 3 quarters · filed 2023-05-11 | $5.79M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $2.83M derived: sum of 2 quarters · filed 2023-03-24 | $4.26M derived: sum of 3 quarters · filed 2023-03-24 | $5.16M 10-K · filed 2023-03-24 |
| 2021-09-30 | $1.24M 10-Q · filed 2022-11-10 | $2.67M derived: sum of 2 quarters · filed 2022-11-10 | $3.57M 10-Q · filed 2022-11-10 | $4.22M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.43M 10-Q · filed 2022-08-11 | $2.32M 10-Q · filed 2022-08-11 | $2.98M derived: sum of 3 quarters · filed 2022-08-11 | $3.29M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $897.00K 10-Q · filed 2022-05-10 | $1.55M derived: sum of 2 quarters · filed 2022-05-10 | $1.86M derived: sum of 3 quarters · filed 2022-05-10 | $1.91M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $652.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $961.00K derived: sum of 2 quarters · filed 2022-03-21 | $1.01M derived: sum of 3 quarters · filed 2022-03-21 | $1.01M 10-K · filed 2022-03-21 |
| 2020-09-30 | $309.00K 10-Q · filed 2021-11-15 | $357.00K derived: sum of 2 quarters · filed 2021-11-15 | $357.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $48.00K 10-Q · filed 2021-08-04 | $48.00K 10-Q · filed 2021-08-04 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $1.05M derived: sum of 2 quarters · filed 2020-03-02 | $1.37M derived: sum of 3 quarters · filed 2020-03-02 | $1.80M 10-K · filed 2020-03-02 |
| 2018-09-30 | $1.05M 10-Q · filed 2019-11-12 | $1.37M derived: sum of 2 quarters · filed 2019-11-12 | $1.80M 10-Q · filed 2019-11-12 | $2.09M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $318.00K 10-Q · filed 2019-08-09 | $748.00K 10-Q · filed 2019-08-09 | $1.03M derived: sum of 3 quarters · filed 2020-03-02 | $1.33M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $430.00K 10-Q · filed 2019-05-09 | $717.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.01M derived: sum of 3 quarters · filed 2020-03-02 | $1.01M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $287.00K derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | $582.00K derived: sum of 2 quarters · filed 2020-03-02 | $582.00K derived: sum of 3 quarters · filed 2020-03-02 | $600.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $295.00K 6-K · filed 2018-11-13 | $295.00K derived: sum of 2 quarters · filed 2018-11-13 | $313.00K 6-K · filed 2018-11-13 | |
| 2017-06-30 | $0.00 derived: 6-K 6 month − 6-K 3 month · filed 2018-08-14 | $18.00K 6-K · filed 2018-08-14 | ||
| 2017-03-31 | $18.00K 6-K · filed 2018-05-15 | |||
| 2016-12-31 | $28.00K 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |